Evidence map›Paper›PMID 30292088›Full record

ArticleNeuroImage. Clinical2018

White matter hyperintensities are linked to future cognitive decline in de novo Parkinson's disease patients.

Mahsa Dadar, Yashar Zeighami, Yvonne Yau, Seyed-Mohammad Fereshtehnejad, Josefina Maranzano, Ronald B Postuma, Alain Dagher, D Louis Collins

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NeuroImage. Clinical, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 72 citations in OpenAlex.

  1. Article
  2. Article
  3. Investigating the impact of white matter hyperintensities on longitudinal progression in progressive supranuclear palsy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Article
  4. Racial and ethnic differences in white matter hypointensities: The role of vascular risk factors.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  5. The role ofFrontiers in neuroscience · 2025
    Review
  6. Article
  7. Cognitive function in Parkinson's disease: associations with perivascular space in basal ganglia.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Review
  15. Article
  16. Article
  17. Observational
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Mahsa DadarMontreal Neurological Institute, McGill University, Montreal, Quebec, Canada; NeuroImaging and Surgical Tools Laboratory, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada. Electronic address: mahsa.dadar@mail.mcgill.ca.
Yashar ZeighamiMontreal Neurological Institute, McGill University, Montreal, Quebec, Canada. Electronic address: yashar.zeighami@mail.mcgill.ca.
Yvonne YauMontreal Neurological Institute, McGill University, Montreal, Quebec, Canada. Electronic address: yvonne.yau@mail.mcgill.ca.
Seyed-Mohammad FereshtehnejadMontreal Neurological Institute, McGill University, Montreal, Quebec, Canada; Division of Neurology, Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. Electronic address: sm.fereshtehnejad@mail.mcgill.ca.
Josefina MaranzanoMontreal Neurological Institute, McGill University, Montreal, Quebec, Canada. Electronic address: jmaranzano@mrs.mni.mcgill.ca.
Ronald B PostumaMontreal Neurological Institute, McGill University, Montreal, Quebec, Canada. Electronic address: ron.postuma@muhc.mcgill.ca.
Alain DagherMontreal Neurological Institute, McGill University, Montreal, Quebec, Canada. Electronic address: alain.dagher@mcgill.ca.
D Louis CollinsMontreal Neurological Institute, McGill University, Montreal, Quebec, Canada; NeuroImaging and Surgical Tools Laboratory, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada. Electronic address: louis.collins@mcgill.ca.
Montreal Neurological Institute and Hospital · CAMcGill University · CAUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

White Matter Hyperintensities (WMHs) are associated with cognitive decline in aging and Alzheimer's disease. However, the pathogenesis of cognitive decline in Parkinson's disease (PD) is not as clearly related to vascular causes, and therefore the role of WMHs as a marker of small-vessel disease (SVD) in PD is less clear. Currently, SVD in PD is assessed and treated independently of the disease. However, if WMH as the major MRI sign of SVD has a higher impact on cognitive decline in PD patients than in healthy controls, vascular pathology needs to be assessed and treated with a higher priority in this population. Here we investigate whether the presence of WMHs leads to increased cognitive decline in de novo PD, and if these effects relate to cortical atrophy. WMHs and cortical thickness were measured in de novo PD patients and age-matched controls (N

Indexed as

AgedAged, 80 and overAgingAtrophyCognitive DysfunctionFemaleFrontal LobeHumansMagnetic Resonance ImagingMaleMiddle AgedNeuropsychological TestsParkinson DiseaseWhite MatterCognitive declineDe novo patientsMagnetic resonance imagingParkinson's diseaseWhite matter hyperintensities

Identifiers

PMID30292088
PMCPMC6176552
OpenAlexW2894235392

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.